 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...182183184185186187188189190191192...235236» |
- || prexasertib (ACR-368) / Acrivon Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 30, 2018
P1b, N=205, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Apr 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Feb 2020
- |||| MB-6 / Microbio
Phase classification, Trial completion date, Trial primary completion date, Surgery: A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer. (clinicaltrials.gov) - Mar 30, 2018
P, N=184, Recruiting, Sponsor: Microbio Co Ltd
Trial completion date: Apr 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Feb 2020 Phase classification: P=N/A --> P | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial initiation date, BRCA Biomarker, PARP Biomarker, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Mar 29, 2018
P2, N=110, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
Phase classification: P=N/A --> P | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Initiation date: Jan 2018 --> May 2018
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Combination therapy: NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 29, 2018
P2, N=22, Not yet recruiting, Sponsor: University of Florida
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Trial primary completion date, Surgery, Metastases: Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 27, 2018
P1, N=8, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Initiation date: Jan 2018 --> May 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Mar 2018
- ||||| EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
Trial initiation date, Metastases: EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) - Mar 27, 2018
P3, N=214, Not yet recruiting, Sponsor: SynCore Biotechnology Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Mar 2018 Initiation date: Mar 2018 --> Jul 2018
- | Enrollment change, Trial withdrawal, Combination therapy, Metastases: Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC (clinicaltrials.gov) - Mar 27, 2018
P2, N=0, Withdrawn, Sponsor: Fujian Cancer Hospital
Initiation date: Mar 2018 --> Jul 2018 N=60 --> 0 | Not yet recruiting --> Withdrawn
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Metastases: AIO-NIFE-trial: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (clinicaltrials.gov) - Mar 23, 2018
P2, N=92, Recruiting, Sponsor: AIO-Studien-gGmbH
N=60 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
Clinical, Journal: Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. (Pubmed Central) - Mar 23, 2018
From 1996 to 2002, 119 patients received an adjuvant 4-drug chemotherapy regimen of 5-fluorouracil, leucovorin, MMC, and dipyridamole with chemoradiation on 2 consecutive trials (trials A and B)...This is the first study to report long-term outcomes of MMC with 5-fluorouracil-based adjuvant chemoradiation in periampullary cancers. Because MMC may be considered in DNA repair-deficient carcinomas, randomized trials are needed to determine the true benefit of adjuvant MMC.
- |||| Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: INTEGA: Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (clinicaltrials.gov) - Mar 23, 2018
P2, N=97, Recruiting, Sponsor: AIO-Studien-gGmbH
Because MMC may be considered in DNA repair-deficient carcinomas, randomized trials are needed to determine the true benefit of adjuvant MMC. Not yet recruiting --> Recruiting
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Mar 22, 2018
P1, N=280, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting N=215 --> 280 | Trial completion date: Oct 2019 --> Jan 2022 | Trial primary completion date: Oct 2019 --> Jan 2022
- ||||| EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
Trial initiation date, Metastases: EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) - Mar 22, 2018
P3, N=214, Not yet recruiting, Sponsor: SynCore Biotechnology Co., Ltd.
N=215 --> 280 | Trial completion date: Oct 2019 --> Jan 2022 | Trial primary completion date: Oct 2019 --> Jan 2022 Initiation date: Dec 2017 --> Mar 2018
- | thioguanine / Generic mfg.
Enrollment closed: AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 21, 2018
P3, N=9022, Active, not recruiting, Sponsor: Children's Oncology Group
Initiation date: Dec 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- | Odomzo (sonidegib) / Sun Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 21, 2018
P1b, N=39, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Trial completion date: Apr 2018 --> Aug 2018 | Trial primary completion date: Apr 2018 --> Aug 2018
- | Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Mar 21, 2018
P2, N=6, Active, not recruiting, Sponsor: University of Miami
Trial completion date: Apr 2018 --> Aug 2018 | Trial primary completion date: Apr 2018 --> Aug 2018 Trial completion date: Apr 2019 --> Jun 2021 | Trial primary completion date: Mar 2017 --> Jun 2020
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Trial completion, Metastases: Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer (clinicaltrials.gov) - Mar 20, 2018
P2, N=27, Completed, Sponsor: Beth Israel Medical Center
Trial completion date: Apr 2019 --> Jun 2021 | Trial primary completion date: Mar 2017 --> Jun 2020 Recruiting --> Completed
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial primary completion date: Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Mar 20, 2018
P2, N=34, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020
- || Ukoniq (umbralisib) / TG Therap
Trial completion date, Trial primary completion date, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 20, 2018
P1, N=65, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Nov 2017 --> Jun 2018
- | New trial, Metastases: Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 18, 2018
P=N/A, N=41, Completed, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial: Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria (clinicaltrials.gov) - Mar 18, 2018
P3, N=252, Recruiting, Sponsor: Sun Yat-sen University
- || Biomarker, Trial completion date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 16, 2018
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Nov 2017 --> Jun 2018 Trial completion date: Oct 2020 --> Dec 2021 | Trial primary completion date: May 2017 --> May 2019
- || BNT321 / BioNTech
Trial completion date, Trial primary completion date, Monotherapy: MV-0715-CP-001.01: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies (clinicaltrials.gov) - Mar 16, 2018
P1, N=68, Recruiting, Sponsor: MabVax Therapeutics, Inc.
Trial completion date: Oct 2020 --> Dec 2021 | Trial primary completion date: May 2017 --> May 2019 Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- | New P3 trial, Metastases: HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC (clinicaltrials.gov) - Mar 15, 2018
P3, N=300, Recruiting, Sponsor: Sun Yat-sen University
- || pegilodecakin (LY3500518) / Eli Lilly
Trial completion date, Trial primary completion date: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 15, 2018
P1, N=350, Active, not recruiting, Sponsor: ARMO BioSciences
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Mar 2018 --> Mar 2020 | Trial primary completion date: Feb 2018 --> Feb 2020
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial initiation date, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 15, 2018
P2, N=45, Not yet recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial completion date: Mar 2018 --> Mar 2020 | Trial primary completion date: Feb 2018 --> Feb 2020 Initiation date: Feb 2018 --> Aug 2018
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open: Post Marketing Surveillance Study for ONIVYDE (clinicaltrials.gov) - Mar 15, 2018
P=N/A, N=78, Recruiting, Sponsor: Shire
Initiation date: Feb 2018 --> Aug 2018 Not yet recruiting --> Recruiting
- | New P1 trial, Metastases: Short-course Radiotherapy (5 (clinicaltrials.gov) - Mar 14, 2018
P1, N=9, Not yet recruiting, Sponsor: Fujian Medical University Union Hospital
- | Rituxan (rituximab) / Roche
Enrollment closed: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 14, 2018
P2, N=53, Active, not recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Terminated --> Active, not recruiting
- | Enrollment closed, Trial completion date, Trial primary completion date, Surgery, Metastases: CAOAROAIO-12: Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Mar 14, 2018
P2, N=311, Active, not recruiting, Sponsor: Prof. Dr. med. Claus R
Terminated --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2018 --> Jun 2018
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: TRUST: Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (clinicaltrials.gov) - Mar 14, 2018
P2, N=49, Completed, Sponsor: Azienda Ospedaliero, Universitaria Pisana
Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2018 --> Jun 2018 Active, not recruiting --> Completed
- | cisplatin / Generic mfg., irinotecan / Generic mfg., gemcitabine / Generic mfg.
New P2 trial, Metastases: NIFTY: mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line (clinicaltrials.gov) - Mar 13, 2018
P2, N=118, Recruiting, Sponsor: Seoul National University Bundang Hospital
- | Vectibix (panitumumab) / Amgen
Enrollment change: Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 13, 2018
P2, N=11, Terminated, Sponsor: University of Nebraska
Active, not recruiting --> Completed N=23 --> 11
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Metastases: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies (clinicaltrials.gov) - Mar 12, 2018
P1, N=79, Active, not recruiting, Sponsor: University of Chicago
N=23 --> 11 Trial completion date: Aug 2018 --> Aug 2020
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date, Metastases: Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) (clinicaltrials.gov) - Mar 9, 2018
P1b, N=220, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Aug 2018 --> Aug 2020 Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018
- | Cyramza (ramucirumab) / Eli Lilly
Trial completion, Trial completion date, Combination therapy, Metastases: A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI (clinicaltrials.gov) - Mar 8, 2018
P2, N=29, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Feb 2018
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Escalated Dose of Irinotecan in mCRC (clinicaltrials.gov) - Mar 8, 2018
P=N/A, N=320, Recruiting, Sponsor: Jaw-Yuan Wang, MD, PhD
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Feb 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | leucovorin calcium / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: ACTHYF: Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (clinicaltrials.gov) - Mar 7, 2018
P3, N=175, Completed, Sponsor: Institut Jerome Lejeune
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017 | Trial primary completion date: Dec 2017 --> Dec 2017
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Mar 7, 2018
P2, N=116, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017 | Trial primary completion date: Dec 2017 --> Dec 2017 Trial completion date: Nov 2019 --> Sep 2019
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: CCRe-IV: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (clinicaltrials.gov) - Mar 6, 2018
P4, N=336, Recruiting, Sponsor: Hospital Universitari de Bellvitge
Trial completion date: Nov 2019 --> Sep 2019 Trial primary completion date: Nov 2017 --> Nov 2018
- || ensituximab (NEO-102) / ImmunityBio
Trial completion date, Metastases: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov) - Mar 5, 2018
P2, N=81, Active, not recruiting, Sponsor: Precision Biologics, Inc
Trial primary completion date: Nov 2017 --> Nov 2018 Trial completion date: Oct 2017 --> Sep 2018
- | Trial initiation date: Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy (clinicaltrials.gov) - Feb 28, 2018
P3, N=764, Not yet recruiting, Sponsor: LI XIN-XIANG
Trial completion date: Oct 2017 --> Sep 2018 Initiation date: Jan 2018 --> Jun 2018
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Phase classification, Trial completion date, Trial primary completion date, Metastases: MM-398-07-02-03: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 28, 2018
P1/2, N=204, Recruiting, Sponsor: Ipsen
Initiation date: Jan 2018 --> Jun 2018 Phase classification: P2 --> P1/2 | Trial primary completion date: Oct 2018 --> Oct 2019 | Trial completion date: Apr 2019 --> Apr 2022
- || eftozanermin alfa (ABBV-621) / AbbVie, Apogenix
Enrollment change: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - Feb 28, 2018
P1, N=150, Recruiting, Sponsor: AbbVie
Phase classification: P2 --> P1/2 | Trial primary completion date: Oct 2018 --> Oct 2019 | Trial completion date: Apr 2019 --> Apr 2022 N=92 --> 150
- bemarituzumab (AMG 552) / Amgen
Phase classification, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (clinicaltrials.gov) - Feb 27, 2018
P1a, N=21, Recruiting, Sponsor: Five Prime Therapeutics, Inc.
N=92 --> 150 Phase classification: P1 --> P1a
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New trial: Post Marketing Surveillance Study for ONIVYDE (clinicaltrials.gov) - Feb 27, 2018
P=N/A, N=78, Not yet recruiting, Sponsor: Shire
- | Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Surgery, Metastases: Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer (clinicaltrials.gov) - Feb 26, 2018
P2, N=20, Completed, Sponsor: Fox Chase Cancer Center
Phase classification: P1 --> P1a Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Feb 23, 2018
P2, N=38, Recruiting, Sponsor: howard safran
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018 N=25 --> 38
- | Hepacid (pegargiminase) / Polaris Pharma
Phase classification, Enrollment change, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 23, 2018
P1/2, N=225, Recruiting, Sponsor: Polaris Group
N=25 --> 38 Phase classification: P1 --> P1/2 | N=148 --> 225
- || Biomarker, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 23, 2018
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1/2 | N=148 --> 225 Trial primary completion date: Oct 2020 --> May 2017
- |||||| Opdivo (nivolumab) / BMS
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: CheckMate 9X8: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (clinicaltrials.gov) - Feb 23, 2018
P2/3, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2020 --> May 2017 Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Aug 2022 | Initiation date: Mar 2018 --> Feb 2018 | Trial primary completion date: Aug 2021 --> Aug 2021